Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). Its lead DMD product candidate is ezutromid, which is an orally administered small molecule. Its lead CDI product candidate is ridinilazole, which is an orally administered small molecule antibiotic. Its Ridinilazole is in Phase II clinical trials. It has conducted over three Phase I clinical trials of ezutromid. Its DMD program is based on utrophin modulation. It has received an orphan drug designation to ezutromid for the treatment of DMD. It is also developing an earlier-stage pipeline of second and future generation utrophin modulators for the treatment of DMD.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Manufacturers - Other
- Sub-Industry: N/A
- Symbol: NASDAQ:SMMT
- CUSIP: N/A
- Web: www.summitplc.com
- Market Cap: $147.3 million
- Outstanding Shares: 12,378,000
- 50 Day Moving Avg: $11.21
- 200 Day Moving Avg: $11.06
- 52 Week Range: $5.31 - $19.75
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -23.80
- P/E Growth: 0.00
- Annual Revenue: $3.05 million
- Price / Sales: 48.29
- Book Value: ($0.37) per share
- Price / Book: -32.16
- EBIDTA: ($31,850,000.00)
- Return on Equity: -161.52%
- Return on Assets: -82.65%
- Current Ratio: 3.85%
- Quick Ratio: 3.85%
- Average Volume: 11,850 shs.
- Beta: 0.12
- Short Ratio: 3.25
Frequently Asked Questions for Summit Therapeutics PLC (NASDAQ:SMMT)
What is Summit Therapeutics PLC's stock symbol?
Summit Therapeutics PLC trades on the NASDAQ under the ticker symbol "SMMT."
Where is Summit Therapeutics PLC's stock going? Where will Summit Therapeutics PLC's stock price be in 2017?
6 analysts have issued twelve-month price objectives for Summit Therapeutics PLC's shares. Their predictions range from $24.00 to $30.00. On average, they expect Summit Therapeutics PLC's stock price to reach $27.40 in the next twelve months. View Analyst Ratings for Summit Therapeutics PLC.
Are investors shorting Summit Therapeutics PLC?
Summit Therapeutics PLC saw a decrease in short interest in the month of April. As of April 13th, there was short interest totalling 44,841 shares, a decrease of 3.7% from the March 31st total of 46,553 shares. Based on an average daily trading volume, of 14,422 shares, the short-interest ratio is currently 3.1 days.
Who are some of Summit Therapeutics PLC's key competitors?
When did Summit Therapeutics PLC IPO?
(SMMT) raised $40 million in an initial public offering (IPO) on Thursday, March 5th 2015. The company issued 3,500,000 shares at $11.54 per share. JMP Securities and Oppenheimer & Co. acted as the underwriters for the IPO and Needham was co-manager.
Who owns Summit Therapeutics PLC stock?
Summit Therapeutics PLC's stock is owned by a number of of retail and institutional investors. Top institutional investors include Lansdowne Partners UK LLP (7.51%), Point72 Asset Management L.P. (6.47%), AXA (2.38%), First Eagle Investment Management LLC (1.41%), Sphera Funds Management LTD. (1.19%) and Granite Point Capital Management L.P. (0.95%). View Institutional Ownership Trends for Summit Therapeutics PLC.
Who sold Summit Therapeutics PLC stock? Who is selling Summit Therapeutics PLC stock?
Who bought Summit Therapeutics PLC stock? Who is buying Summit Therapeutics PLC stock?
How do I buy Summit Therapeutics PLC stock?
Shares of Summit Therapeutics PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Summit Therapeutics PLC stock cost?
One share of Summit Therapeutics PLC stock can currently be purchased for approximately $11.90.
Earnings History for Summit Therapeutics PLC (NASDAQ:SMMT)Earnings History by Quarter for Summit Therapeutics PLC (NASDAQ:SMMT)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/27/2015||Q215||($0.06)||($0.55)||$0.39 million||$0.67 million||View||Listen|
Earnings Estimates for Summit Therapeutics PLC (NASDAQ:SMMT)
2017 EPS Consensus Estimate: ($1.92)
2018 EPS Consensus Estimate: ($1.43)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Summit Therapeutics PLC (NASDAQ:SMMT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Summit Therapeutics PLC (NASDAQ:SMMT)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Summit Therapeutics PLC (NASDAQ:SMMT)
Latest Headlines for Summit Therapeutics PLC (NASDAQ:SMMT)
Summit Therapeutics PLC (SMMT) Chart for Thursday, May, 25, 2017